What are the treatment regimens for omacetaxine (Synribo) in the treatment of chronic myelogenous leukemia (CML)?

Updated: Oct 23, 2019
  • Author: Rossa Khalaf, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Omacetaxine (Synribo) is a protein translation inhibitor that is indicated for chronic- or accelerated-phase CML with resistance and/or intolerance to two or more TKIs (eg, dasatinib, nilotinib, imatinib). [20, 21] Regimens are as follows:

  • Induction: 1.25 mg/m 2 SC twice daily for 14 consecutive days of a 28-day treatment cycle; repeat cycles until hematologic response is achieved
  •  Maintenance: 1.25 mg/m 2 SC twice daily for 7 consecutive days q 28 days; continue as long as clinically beneficial

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!